

June 4, 2025

Colorado Congressional Delegation
United States Congress
Washington, D.C. 20515

Honorable Members of the Colorado Congressional Delegation:

As stakeholders representing Colorado’s health care and life sciences community — including the Colorado BioScience Association, the Fitzsimons Innovation Community, patient advocates, and other leaders in research, clinical care, and biotechnology — we write to express our deep concerns regarding the recent Executive Order establishing a “Most-Favored-Nation” (MFN) drug pricing policy.

While we strongly support efforts to make prescription drugs more affordable for patients, we believe this policy, as currently proposed, poses a serious threat to Colorado’s thriving biomedical innovation ecosystem and, by extension, to the patients we serve both here at home and around the world.

The MFN policy ties U.S. drug reimbursement rates to the lowest prices paid in foreign countries — a model that does not reflect the unique structure, costs, or incentives that fuel innovation in the United States. For Colorado’s medical research institutions, this policy creates a chilling effect on investment, jeopardizes ongoing research and development efforts, and undermines our ability to bring breakthrough therapies from the lab to the bedside.

Our state has long been a leader in advancing biomedical science and fostering public-private collaboration. The Fitzsimons Innovation Community and the CU Anschutz Medical Campus are home to hundreds of startups, researchers, and clinicians working at the frontier of science — from next-generation cancer treatments to personalized medicine. These breakthroughs are made possible by a delicate ecosystem of public funding, private capital, and forward-looking policy. The MFN model threatens to destabilize that balance.

Rather than importing European-style price controls to the U.S., we should instead be encouraging our allies and trading partners to pay their fair share for the research and innovation that is saving lives around the world. Global access and affordability must be achieved without undermining the very system that produces the cures.

We are also concerned that the implementation of MFN pricing, particularly without adequate stakeholder input or a rigorous economic impact analysis, could lead to unintended consequences — including reduced access to essential medicines, delayed development of novel therapies, and long-term harm to Colorado’s competitiveness as a center for life sciences.

We urge you to work with your colleagues in Congress to oppose implementation of this policy in its current form, and instead to support solutions that lower drug prices while preserving incentives for medical innovation. As leaders in one of the nation’s most dynamic biomedical communities, we stand ready to partner with you to craft balanced reforms that promote affordability, access, and innovation.

Thank you for your service and your ongoing support of Colorado’s health and science sectors.

Respectfully,

